Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 18, 2025. 

NeurologyLive® Friday 5 — April 18, 2025

Videos

The resident in the Department of Neurology at NYU Langone Health discussed the preliminary findings of a 9-month study on lecanemab recently presented at the 2025 AAN Annual Meeting. [WATCH TIME: 2 minutes]

Evaluating Safety and Early Outcomes of Lecanemab Treatment for Alzheimer Disease: Philip Kuball, MD

In a randomized cross-over trial, 4 of 5 commonly used drugs for idiopathic intracranial hypertension reduced intracranial pressure; however, also exacerbated cognitive issues.

Common Idiopathic Intracranial Hypertension Drugs Show Modest Intracranial Pressure Reduction, With Noted Adverse Effects 

The former FDA commissioner discussed the collaborative power of the neuromuscular community and the challenges of implementing emerging therapies in a rapidly evolving care landscape. [WATCH TIME: 4 minutes]

Preparing for the Future of Rare Disease Treatment: Robert Califf, MD

Resident in the Department of Neurology at NYU Langone Health.

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nancy Foldvary-Schaefer, DO, FAAN. [LISTEN TIME: 25 minutes]

Episode 139: Sleep and Seizures: Emerging Insights From AAN 2025

The executive vice president of research at the National MS Society talked about how the award continues to honor transformative multiple sclerosis research and inspire the next generation of investigators. [WATCH TIME: 5 minutes]

Celebrating Innovation in MS Research With the John Dystel Prize: Bruce Bebo, PhD

The chief scientific officer of the Parkinson’s Foundation discussed the foundation’s efforts to integrate whole genome sequencing into PD GENEration and expand access across diverse global populations. [WATCH TIME: 4 minutes]

Expanding Access to Whole Genome Sequencing in Parkinson Research: James Beck, PhD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AAN 2025

AD/PD 2025

MDA 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Updates in the Management of Relapsing Multiple Sclerosis

Fred Lublin, MD; Patricia K. Coyle, MD; Mark Freedman, MD; and Scott D. Newsome, DO, discuss a number of topics pertaining to the diagnosis of multiple sclerosis, including a focus on fatigue and its impact on quality of life.

2017 Changes to the McDonald Criteria: Diagnosing Multiple Sclerosis 

Use of MRI in Diagnosing Multiple Sclerosis 

Misdiagnosis of Multiple Sclerosis

Cerebrospinal Fluid in Diagnosing Multiple Sclerosis

Challenges in Optimally Treating Multiple Sclerosis

 QoL Issues in the Management of Multiple Sclerosis

Multiple Sclerosis Fatigue

TRIUMPHANT-MS Trial: Fatigue in MS

OPTIMUM Phase 3 Trial: Secondary End Point Effect on Fatigue

Strategies for Choosing Initial Therapy in MS

Anti-CD20 Monoclonal Antibodies for Treatment of RMS

Cladribine for Treatment of RMS

S1P Receptor Modulators for Treatment of RMS

Fumarates for Treatment of RMS

The Future of Managing Multiple Sclerosis

Peer Exchange

Clinical

EMD-22-NRD0193 - /clinical/multiple-sclerosis

 Peer Exchange video series features panels of expert physicians engaging in in-depth discussions about practice-changing treatments, challenges in care, and the future paradigm of management for neurologic diseases.

Fumarates for Treatment of RMS

EP: 1.2017 Changes to the McDonald Criteria: Diagnosing Multiple Sclerosis

EP: 2.Use of MRI in Diagnosing Multiple Sclerosis

EP: 3.Misdiagnosis of Multiple Sclerosis

EP: 4.Cerebrospinal Fluid in Diagnosing Multiple Sclerosis

EP: 5.Challenges in Optimally Treating Multiple Sclerosis

EP: 6. QoL Issues in the Management of Multiple Sclerosis

EP: 7.Multiple Sclerosis Fatigue

EP: 8.TRIUMPHANT-MS Trial: Fatigue in MS

EP: 9.OPTIMUM Phase 3 Trial: Secondary End Point Effect on Fatigue

EP: 10.Strategies for Choosing Initial Therapy in MS

EP: 11.Anti-CD20 Monoclonal Antibodies for Treatment of RMS

EP: 12.Cladribine for Treatment of RMS

EP: 13.S1P Receptor Modulators for Treatment of RMS

EP: 14.Fumarates for Treatment of RMS

EP: 15.The Future of Managing Multiple Sclerosis